ONCAlert | 2018 Gastrointestinal Cancers Symposium
Videos  >  

Dr. Elizabeth Plimack on Ipilimumab and PD-L1 Inhibitors in the Treatment of Bladder Cancer

Elizabeth Plimack, MD, MS
Published Online:3:57 PM, Wed January 13, 2016

Elizabeth Plimack, MD, MS, director of Genitourinary Unirnary Research, Fox Chase Cancer Center, discusses the monoclonal antibody ipilimumab and its uncertain efficacy in bladder cancer. Plimack says the efficacy of PD-L1 inhibitors have been proven in the treatment of bladder cancer and are currently employed in the armamentarium of medical professionals. She adds as other cancer types further test both ipilimumab and PD-L1 inhibitors, oncologists will gain a better understanding of how both will continue to play a role in bladder cancer.

Plimack says data presented over the course of the past year will also aid oncologists in potentially utilizing combinations of ipilimumab and chemoimmunotherapies.

Ipilimumab was most recently approved in the adjuvant setting for melanoma, as well as in combination with nivolumab in BRAF V600 wild-type (WT) unresectable or metastatic melanoma. Both approvals arrived in October 2015.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.